Saudi Arabia Inaugurates First Local Insulin Manufacturing Facility
New plant aims to enhance national drug security and address rising diabetes prevalence
In a significant advancement for Saudi Arabia's healthcare sector, the Kingdom has inaugurated its first local insulin manufacturing facility.
This initiative is a collaborative effort between Sanofi, Sudair Pharmaceuticals Company (SPC), and the National Unified Procurement Company (NUPCO), aligning with the objectives of Vision 2030 to achieve pharmaceutical self-sufficiency.
The facility, located in Sudair Industrial City, was officially inaugurated by Minister of Industry and Mineral Resources, Bandar Alkhorayef, on February 13, 2025. Once fully operational, it is projected to produce approximately 15 million insulin pens annually, sufficient to meet the needs of around 500,000 patients across the country.
This production capacity is expected to fulfill 70% of the Kingdom's insulin requirements, significantly reducing reliance on imports.
The establishment of this facility comes in response to the increasing prevalence of diabetes in Saudi Arabia.
In 2021, the International Diabetes Federation reported that 17.7% of the adult population in the country had diabetes, with projections indicating a rise to 21.4% by 2045. The localized production of insulin is anticipated to enhance national drug security and provide more accessible treatment options for the growing number of diabetes patients.
Beyond manufacturing, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills.
This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical innovation.
Sanofi, a global healthcare leader with a presence in Saudi Arabia for over five decades, has been instrumental in this initiative.
The company is transferring its technical expertise and global knowledge in biological technologies to SPC, contributing to the localization of essential biopharmaceutical industries and enhancing economic diversification within the Kingdom.
This initiative is a collaborative effort between Sanofi, Sudair Pharmaceuticals Company (SPC), and the National Unified Procurement Company (NUPCO), aligning with the objectives of Vision 2030 to achieve pharmaceutical self-sufficiency.
The facility, located in Sudair Industrial City, was officially inaugurated by Minister of Industry and Mineral Resources, Bandar Alkhorayef, on February 13, 2025. Once fully operational, it is projected to produce approximately 15 million insulin pens annually, sufficient to meet the needs of around 500,000 patients across the country.
This production capacity is expected to fulfill 70% of the Kingdom's insulin requirements, significantly reducing reliance on imports.
The establishment of this facility comes in response to the increasing prevalence of diabetes in Saudi Arabia.
In 2021, the International Diabetes Federation reported that 17.7% of the adult population in the country had diabetes, with projections indicating a rise to 21.4% by 2045. The localized production of insulin is anticipated to enhance national drug security and provide more accessible treatment options for the growing number of diabetes patients.
Beyond manufacturing, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills.
This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical innovation.
Sanofi, a global healthcare leader with a presence in Saudi Arabia for over five decades, has been instrumental in this initiative.
The company is transferring its technical expertise and global knowledge in biological technologies to SPC, contributing to the localization of essential biopharmaceutical industries and enhancing economic diversification within the Kingdom.